Skip to main content
Top
Published in: Gastric Cancer 3/2013

01-07-2013 | Original Article

Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study

Authors: Shinichi Hasegawa, Chikara Kunisaki, Hidetaka Ono, Takashi Oshima, Shoichi Fujii, Masataka Taguri, Satoshi Morita, Tsutomu Sato, Roppei Yamada, Norio Yukawa, Yasushi Rino, Munetaka Masuda

Published in: Gastric Cancer | Issue 3/2013

Login to get access

Abstract

Background and objectives

We clarified the impact of omentectomy for advanced gastric cancer on patient survival from the surgical results of a high-volume center in Japan.

Methods

Patients who received curative gastrectomy were divided into two groups based on whether they underwent omentectomy. The propensity score-matching method was used to assemble a well-balanced cohort, and relapse-free survival and the pattern of recurrence were compared.

Results

For this study, 330 patients who fulfilled the inclusion criteria participated and were divided into two groups: group R, patients who received omentectomy, and group P, patients who received omentum-preserving gastrectomy. After performing score-matching, 196 patients were selected. The 3- and 5-year relapse-free survival rates were 72.9 % (95 % confidence interval, 64.1–81.7) and 66.2 % (56.6–75.8 %) in group R, and 76.7 % (67.9–81.2) and 67.3 % (55.1–79.5) in group P, which were not significantly different (P = 0.750). Regarding sites of relapses, no differences were observed between the groups (P = 0.863).

Conclusions

In this series, omentum-preserving gastrectomy for advanced gastric cancer did not increase the peritoneal relapse rate or affect patient survival compared to conventional gastrectomy. The non-inferiority of the omission of omentectomy should be evaluated by a randomized controlled trial.
Literature
1.
go back to reference Liebermann-Meffert D. The greater omentum. Anatomy, embryology, and surgical application. Surg Clin N Am 2000;80:275–293, xii Liebermann-Meffert D. The greater omentum. Anatomy, embryology, and surgical application. Surg Clin N Am 2000;80:275–293, xii
2.
go back to reference Platell C, Cooper D, Papadimitriou JM, et al. The omentum. World J Gastroenterol. 2000;6:169–76.PubMed Platell C, Cooper D, Papadimitriou JM, et al. The omentum. World J Gastroenterol. 2000;6:169–76.PubMed
3.
go back to reference Higgins GM, Bain CG. The absorption and transference of particulate material by the great omentum. Surg Gynecol Obstet. 1930;50:851–60. Higgins GM, Bain CG. The absorption and transference of particulate material by the great omentum. Surg Gynecol Obstet. 1930;50:851–60.
4.
go back to reference Hagiwara A, Takahashi T, Sawai K, Taniguchi H, Shimotsuma M, Okano S, et al. Milky-spots as the implantation site for malignant cells in the peritoneal dissemination in mice. Cancer Res. 1993;53:687–92.PubMed Hagiwara A, Takahashi T, Sawai K, Taniguchi H, Shimotsuma M, Okano S, et al. Milky-spots as the implantation site for malignant cells in the peritoneal dissemination in mice. Cancer Res. 1993;53:687–92.PubMed
5.
go back to reference Imada T, Matsumoto A. Mechanism by which peritoneal disseminated metastasis develops in gastric cancer. Nippon Geka Gakkai Zassi 1986;87(6):593–603 (in Japanese). Imada T, Matsumoto A. Mechanism by which peritoneal disseminated metastasis develops in gastric cancer. Nippon Geka Gakkai Zassi 1986;87(6):593–603 (in Japanese).
6.
go back to reference Lawrance RJ, Loizidou M, Cooper AJ, Alexandar P, Taylor I. Importance of the omentum in the development of intra-abdominal metastases. Br J Surg. 1991;78:117–9.PubMedCrossRef Lawrance RJ, Loizidou M, Cooper AJ, Alexandar P, Taylor I. Importance of the omentum in the development of intra-abdominal metastases. Br J Surg. 1991;78:117–9.PubMedCrossRef
7.
go back to reference Hagiwara A, Sawai K, Sakakura C, Shirasu M, Ohgaki M, Yamasaki J, et al. Complete omentectomy and extensive lymphadenectomy with gastrectomy improves the survival of gastric cancer patients with metastases in the adjacent peritoneum. Hepatogastroenterology. 1998;45:1922–9.PubMed Hagiwara A, Sawai K, Sakakura C, Shirasu M, Ohgaki M, Yamasaki J, et al. Complete omentectomy and extensive lymphadenectomy with gastrectomy improves the survival of gastric cancer patients with metastases in the adjacent peritoneum. Hepatogastroenterology. 1998;45:1922–9.PubMed
8.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef
9.
go back to reference Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.PubMedCrossRef Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.PubMedCrossRef
10.
go back to reference Fujita J, Tsukahara Y, Ikeda K, Akagi K, Suga K, Hata S, et al. Evaluation of omentum preserving gastrectomy for advanced gastric cancer. Jpn J Gastroenterol Surg 2003;36:1151–1158 (in Japanese). Fujita J, Tsukahara Y, Ikeda K, Akagi K, Suga K, Hata S, et al. Evaluation of omentum preserving gastrectomy for advanced gastric cancer. Jpn J Gastroenterol Surg 2003;36:1151–1158 (in Japanese).
11.
go back to reference Watanabe N, Nashimoto A, Yabusaki H, Takii Y, Tsuchiya K, Tanaka O. Evaluation of omento-bursectomy for T2 and T3 gastric cancers. Nippon Rinsho Geka Gakkai Zassi 2004;65(10):2570–2574 (in Japanese). Watanabe N, Nashimoto A, Yabusaki H, Takii Y, Tsuchiya K, Tanaka O. Evaluation of omento-bursectomy for T2 and T3 gastric cancers. Nippon Rinsho Geka Gakkai Zassi 2004;65(10):2570–2574 (in Japanese).
12.
go back to reference Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.PubMedCrossRef Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.PubMedCrossRef
13.
go back to reference Ha TK, An JY, Youn HG, Noh JH, Sohn TS, Kim S. Omentum-preserving gastrectomy for early gastric cancer. World J Surg. 2008;32:1703–8.PubMedCrossRef Ha TK, An JY, Youn HG, Noh JH, Sohn TS, Kim S. Omentum-preserving gastrectomy for early gastric cancer. World J Surg. 2008;32:1703–8.PubMedCrossRef
14.
go back to reference Fujita J, Kurokawa Y, Sugimoto T, Miyashiro I, Iijima S, Kimura Y, et al. Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial. Gastric Cancer. 2012;15(1):42–8.PubMedCrossRef Fujita J, Kurokawa Y, Sugimoto T, Miyashiro I, Iijima S, Kimura Y, et al. Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial. Gastric Cancer. 2012;15(1):42–8.PubMedCrossRef
Metadata
Title
Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study
Authors
Shinichi Hasegawa
Chikara Kunisaki
Hidetaka Ono
Takashi Oshima
Shoichi Fujii
Masataka Taguri
Satoshi Morita
Tsutomu Sato
Roppei Yamada
Norio Yukawa
Yasushi Rino
Munetaka Masuda
Publication date
01-07-2013
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 3/2013
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-012-0198-6

Other articles of this Issue 3/2013

Gastric Cancer 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.